作者
John Hixson,David C. Spencer,Kim J. Burchiel,Harish Babu,Robert Beach,Jerry J. Shih,Sharona Ben‐Haim,Rebecca O’Dwyer,Sepehr Sani,Derek G. Southwell,Matthew William Luedke,David Blum,Gautam Banik,Marina Bershteyn,Alessandro Bulfone,Brianna G Feld,Holly Finefrock,Luis C. Fuentealba,Ji-Hye Jung,Tia J. Kowal
摘要
Objective: To present updated findings from a first-in-human, open-label study of NRTX-1001, an allogeneic GABAergic interneuron therapy, for unilateral drug-resistant temporal lobe epilepsy with mesial temporal sclerosis (NCT05135091). Background: NRTX-1001 is an investigational GABAergic interneuron product derived from human pluripotent stem cells. Preclinical studies demonstrated that hippocampal transplantation significantly reduces seizure frequency in a mouse kainic acid model of focal epilepsy (Bershteyn et.al., Cell Stem Cell 30 :1–20, 2023). Between June 2022 and May 2024, ten subjects were enrolled in the ongoing first-in-human study designed to assess the safety and efficacy of NRTX-1001. Design/Methods: Adults participants with drug-resistant unilateral TLE with mesial temporal sclerosis were administered NRTX-1001 via stereotactic surgery into the hippocampal head and body with intraoperative imaging. Immunosuppression was initiated one week prior to the procedure and is scheduled for tapering after one year. The primary endpoint is safety, with secondary endpoints of seizure frequency, neuroimaging, EEG, cognitive function, and visual fields at one-year post-treatment. Results: As of July 2024, five subjects in the low-dose cohort were at least 6 months post-treatment, with two subjects completing 24 and 19 months of follow-up. The low-dose cohort demonstrated an 82% reduction in disabling seizure frequency over the 4–6-month post-treatment period, with 80% achieving a ≥50% responder rate. No treatment-related serious adverse events (SAEs) have been reported. For all treated subjects, three non-treatment-related SAEs were observed. These were not determined to be related to the cells, procedure, or immunosuppression. Preliminary cognitive assessments revealed improvements in select measures of memory function for some subjects. Updated results for all subjects will be presented. Conclusions: NRTX-1001 administration has been well-tolerated in ten patients with drug-resistant TLE, with preliminary data suggesting significant reductions in seizure frequency and potential cognitive improvements. Unlike current surgical treatment options, NRTX-1001 may provide a non-destructive, cell-based therapeutic approach, potentially providing a restorative option for focal epilepsy. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Dr. Hixson has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Hixson has received personal compensation for serving as an employee of Nile Ai. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NextSense Inc. Dr. Hixson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seer Medical. Dr. Hixson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Expert Institute. Dr. Hixson has received personal compensation in the range of $5,000-$9,999 for serving as a Reviewer with Epilepsy Study Consortium. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuiticals. Dr. Spencer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace Inc. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Various. The institution of Dr. Spencer has received research support from NIH. Dr. Spencer has received publishing royalties from a publication relating to health care. Dr. Spencer has received personal compensation in the range of $500-$4,999 for serving as a Faculty in Teaching Course supported by unrestricted educational grants with Creative Education Concepts. Kim Burchiel has nothing to disclose. Harish Babu has nothing to disclose. The institution of Dr. Beach has received research support from Neurona. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Life. Dr. Shih has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Shih has received research support from Neurona. The institution of Dr. Shih has received research support from NCGS, Inc. Dr. Shih has a non-compensated relationship as a Test Writing Committee Member with ABPN that is relevant to AAN interests or activities. Author has nothing to discloseDr. O'Dwyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. O'Dwyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Sciences. The institution of Sepehr Sani has received research support from NIH. Sepehr Sani has received intellectual property interests from a discovery or technology relating to health care. Sepehr Sani has received publishing royalties from a publication relating to health care. Derek Southwell has nothing to disclose. Dr. Luedke has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bright Health. Dr. Luedke has received personal compensation in the range of $0-$499 for serving as an Expert Witness for Guidepoint. The institution of Dr. Luedke has received research support from US NAVY. The institution of Dr. Luedke has received research support from Neurona. The institution of Dr. Luedke has received research support from Xenon. Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics. Gautam Banik has received personal compensation for serving as an employee of Neurona Therapeutics. Marina Bershteyn has received personal compensation for serving as an employee of Neurona therapeutics. Marina Bershteyn has stock in Neurona therapeutics. Marina Bershteyn has received intellectual property interests from a discovery or technology relating to health care. Dr. Bulfone has received personal compensation for serving as an employee of Neurona Therapeutics Inc. Brianna Feld has received personal compensation for serving as an employee of Neurona Therapeutics. Ms. Finefrock has received personal compensation for serving as an employee of Neurona Therapeutics. Luis Fuentealba has nothing to disclose. Ji-Hye Jung has nothing to disclose. Tia Kowal has received personal compensation for serving as an employee of Neurona Tharapeutics. Tia Kowal has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist with Neurona Theraputics. Sonja Kriks has received personal compensation for serving as an employee of Neurona Therapeutics. Sonja Kriks has stock in Neurona Therapeutics. Sonja Kriks has received intellectual property interests from a discovery or technology relating to health care. Rose Larios has received personal compensation for serving as an employee of Neurona Therapeutics. Seonok Lee has received personal compensation for serving as an employee of Neurona Therapeutics. Author has nothing to discloseYves Maury has received personal compensation for serving as an employee of Neurona Therapeutics. Yves Maury has stock in Neurona therapeutics. Catherine Priest has received personal compensation for serving as an employee of Neurona Therapeutics. Catherine Priest has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk. The institution of Catherine Priest has received research support from CIRM. Sergei Shevchuk has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Joshi has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Joshi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atara Biotherapeutics. Dr. Joshi has stock in Atara Biotherapeutics. Dr. Nicholas has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Nicholas has stock in Neurona Therapeutics. Dr. Nicholas has received intellectual property interests from a discovery or technology relating to health care.